Medovate named ‘‘Best Medical Device Innovation Development Company 2022 - UK” by GHP’s Global Excellence Awards 2022

23rd March, 2022

Pioneering medical device company Medovate have been named ‘Best Medical Device Innovation Development Company 2022’ at Global Health and Pharma’s (GHP) 2022 Global Excellence Awards.

Based in Cambridge, Medovate is a dedicated medical device development vehicle for the NHS and prides itself on working closely with clinicians to develop valuable medical technology innovations with the potential to improve patient safety.

It was awarded the prestigious accolade for its exceptional expertise in guiding clinicial innovators through the entire, and often complex, development pathway – from design, manufacturing, regulation and quality, feasibility testing, and clinical trials, through to product launch, marketing and distribution.

Judges were impressed that in just four years ago, Medovate had established a proven platform to bring medical products to market and has pressed ahead with appointing distributors and building a portfolio of medical devices to improve patient safety relating to the specialist areas of anaesthesia, airway management, critical care and surgery.

Speaking about the award, Managing Director Stuart Thomson said: “We are delighted to receive this award which is testament to the whole Medovate team who have worked so hard to get our first product launched globally, and attain regulatory approval in key markets around the globe.

“Medovate has achieved a great deal in its first few years and is now confidently looking forward, building on all it has achieved so far, expanding its product portfolio and planning new product launches.”

Through its unique medical device development pipeline, the company aims to improve patient care and safety by supplying innovative MedTech solutions to global healthcare systems, which are facing some of the most pressing challenges of the modern era.

At the heart of Medovate’s expanding portfolio is its revolutionary technology SAFIRA® (SAFer Injection for Regional Anaesthesia) – its first product to be brought to market. The system – already launched in key markets across the world, from the United States to the UK and Europe, Australia and New Zealand – has been designed to make injection during regional anaesthesia safer.

The GHP awards recognise and encourage creativity, innovation and quality culture present in companies, organisations and their leaders. The awards help to shine a spotlight on innovation within the pharmaceutical and healthcare industries by recognising those companies who successfully develop crucial new ideas and products and bring them to market to benefit these sectors.

For the full story, take a look at page 25 in the Q1 2022 edition of the Global Health & Pharma Magazine – click here.